Manuel Romero‐Gómez
Consejo Superior de Investigaciones Científicas · 971 works · 59,417 citations · h-index 105
Top works
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
- Treatment of NAFLD with diet, physical activity and exercise
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy
- Advancing the global public health agenda for NAFLD: a consensus statement
- Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment
- Mapping the human genetic architecture of COVID-19
- Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry